Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Procter & Gamble Manufactura S. de R.L. de C.V.
WARNING LETTER
•Procter & Gamble Manufactura S. de R.L. de C.V.•March 21, 2023

Procter & Gamble Manufactura S. de R.L. de C.V. – FDA Warning Letter, Mar 21, 2023

Record Details

The FDA issued a Warning Letter to Ms. Burke concerning the drug listing information for Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion (NDC 58933-541). An FDA review identified contradictory information between the product's labeling and its electronic listing file (eDRLS/SPL). Specifically, the active ingredients on the labeling (acetaminophen, dextromethorphan hbr, doxylamine succinate, and phenylephrine) did not match those in the SPL file, which incorrectly included guaifenesin and omitted doxylamine. This constitutes a failure to fulfill listing obligations under Section 510(j) of the FD&C Act and 21 CFR Part 207, making it a prohibited act under Section 301(p). Furthermore, the improper listing renders the drug misbranded under Section 502(o) and in violation of Section 301(a). The FDA emphasized that accurate drug listing is crucial for patient safety, inspections, and supply chain security. The firm's product data was previously removed from the Online NDC Directory due to these deficiencies. The firm must respond within 15 working days, detailing corrective actions and preventative measures. Failure to adequately address these violations could lead to legal actions such as seizure and injunction, and the deficient listing data will be inactivated.

Company
Procter & Gamble Manufactura S. de R.L. de C.V.
Inspection date
March 21, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Tina Smith (Director)
View Company Profile

ID · e6fb5156-1f3e-42c6-b159-f870c34b5b79

Violation Codes10
FD&C Act 510(j)21 CFR 20721 CFR 207.49(a)(4)21 U.S.C. 360(j)21 U.S.C. 331(p)FD&C Act 301(p)FD&C Act 502(o)21 U.S.C. 352(o)FD&C Act 301(a)21 CFR 207.57(b)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Procter & Gamble Manufactura S. de R.L. de C.V.
  • 483 - 2025-06-27June 27, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Procter & Gamble Manufactura S. de R.L. de C.V.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.